The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI).
 
Dimitra Rafailia Bakaloudi
No Relationships to Disclose
 
Rafee Talukder
No Relationships to Disclose
 
Dimitrios Makrakis
No Relationships to Disclose
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Ubenthira Patgunarajah
No Relationships to Disclose
 
Vinay Mathew Thomas
No Relationships to Disclose
 
Tanya Jindal
No Relationships to Disclose
 
Jason R Brown
Honoraria - AstraZeneca
Speakers' Bureau - EMD Serono
Research Funding - Bicycle Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Seagen (Inst)
 
Marija Miletic
No Relationships to Disclose
 
Jeffrey Johnson
No Relationships to Disclose
 
Gavin Hui
No Relationships to Disclose
 
Lucia Alonso Buznego
No Relationships to Disclose
 
Rafael Morales-Barrera
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck/Pfizer; MSD; Sanofi
Speakers' Bureau - Astellas Pharma; Merck/Pfizer; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; MSD; Pfizer; Roche/Genentech; Sanofi
 
David Humberto Marmolejo Castañeda
No Relationships to Disclose
 
Charles B Nguyen
No Relationships to Disclose
 
Pedro C. Barata
Honoraria - UroToday
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst)
 
Tyler F. Stewart
Consulting or Advisory Role - Seattle Genetics/Astellas
Research Funding - GRAIL
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Gilead Sciences; Merck; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Fresenius Kabi; G1 Therapeutics; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Pfizer; PureTech; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Ali Raza Khaki
Honoraria - HMP; OncLive/MJH Life Sciences
Consulting or Advisory Role - Gilead Sciences (Inst)
Research Funding - 23andMe (Inst); Janssen Oncology (Inst)
Other Relationship - Tempus
(OPTIONAL) Uncompensated Relationships - Janssen; Seattle Genetics/Astellas